Tepnel Completes Acquisition of GenXTrak™ DNA Extraction Business from Whatman
News Mar 02, 2006
The Cambridge-based GenXTrak™ business will now operate within Tepnel's service division, offering extraction, purification, quantification and normalisation of clinical DNA samples.
The acquisition expands Tepnel's access to the pharmacogenomics testing market and positions the Company as one of Europe's largest providers of DNA extraction services.
Commenting on the acquisition, Ben Matzilevich CEO, said, "The acquisition of GenXTrak fits neatly into Tepnel's Research Products & Services division ceating additional capacity for our existing nucleic acid purification business."
"This business will provide access to European based customers and expand our menu of capabilities allowing us to handle a variety of sample types. An important component of Tepnel's strategic plan is to provide expanded capabilities in both genetic and protein analysis."
"In order to compete in these markets Tepnel must be able to provide low cost, high throughput services while meeting pharmaceutical standards. We plan to automate the Whatman facility to improve our competitive position."
"Once implemented in Cambridge we plan to expand these capabilities into our Edinburgh, Scotland and Stamford, USA facilities."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.